Manager TitleAgeSince
President 63 2010-05-26
Director TitleAgeSince
Director/Board Member 63 2010-03-25
Director/Board Member 85 2011-05-31
Director/Board Member 79 2013-05-08
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%+0.40% - - 0
-4.31%-6.62%+65.79%+98.02% 72.12B
-4.19%+1.05%+52.79%+85.53% 65.85B
-3.22%+23.17%+1.75%-5.23% 29.28B
-1.42%-3.38%-5.99%+465.34% 27.47B
+2.59%+2.63%+49.82%+12.42% 26.7B
-1.81%+0.38%+34.52%-18.33% 20.06B
+5.36%+4.61%+270.18%+415.10% 18.22B
-1.53%-5.16%+9.51%+508.52% 16.4B
+0.87%+4.26%+41.21%+150.80% 13.4B
Average -0.77%+5.35%+57.73%+190.24% 32.17B
Weighted average by Cap. -2.09%+3.13%+54.44%+149.29%
Logo TESARO Inc
TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.
Employees
-